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Background
The regenerative capacity of mesenchymal stem cells
(MSCs) is contingent on their content of multipotent
progenitors [1]. Despite its importance to the efficacy of
MSC therapies, the clonal heterogeneity of MSCs
remains poorly defined. To address this deficiency, the
current study presents a novel high-capacity assay to
quantify the clonal heterogeneity in MSC potency and
demonstrates its utility to resolve regenerative properties
as a function of potency. Human bone marrow was the
source of MSCs in this study. The versatility and acces-
sibility of marrow-derived MSCs make them a standard
for many therapeutic applications.
Materials and methods
Primary MSCs were harvested from the iliac crest bone
marrow of healthy adult volunteers and cultured as pre-
viously described [2]. The in vitro assay developed for
this study utilizes a 96-well format to (1) clone fluores-
cent MSCs stained with CellTracker Green by limiting
dilution, (2) generate matched clonal colonies, (3) differ-
entiate 3 matched colonies per clone to quantify triline-
age potential to exhibit adipo-, chondro- and
osteogenesis as a measure of potency, and (4) cryopre-
serve the 4th matched colony of each clone in situ in an
undifferentiated state for future use. Clones of known
potency were evaluated for their colony-forming effi-
ciency as a measure of proliferation potential [3].
Expression of the heterotypic cell adhesion molecule
CD146 on the surface of MSC clones was measured
with flow cytometry.
Results
All eight categories of trilineage potential were detected
in human marrow MSCs. Multipotent MSCs had a
higher proliferation potential than lineage-committed
MSCs. Tripotent clones formed colonies with a median
efficiency of 50%, as compared with 14% and 1% for bi-
and unipotent clones, respectively (p < 0.01). Likewise,
colonies that formed from tripotent clones had the lar-
gest median diameter. CD 1 4 6m a yb eab i o m a r k e ro f
MSC potency. Histograms of fluorescence intensity from
pooled tripotent clones labeled with anti-CD146 anti-
body shifted to higher CD146 expression relative to the
parent MSC preparation from which the clones were
generated; whereas, the histograms for parent MSCs and
their unipotent progeny were similar. In particular, the
mean fluorescence intensity of tripotent clones was
nearly twice the value for the parent and unipotent
MSCs (p < 0.05).
Conclusions
The research presented here addresses a basic deficiency
in stem cell technology by developing a quantitative and
high-capacity assay to characterize the clonal heteroge-
neity of MSC potency. The data suggest a complex hier-
archy of lineage commitment in which proliferation
potential and CD146 expression diminish with loss of
potency. The capacity of multipotent MSCs for ex vivo
expansion and their differential expression of a potential
potency marker will facilitate rapid production of effica-
cious MSC therapies with consistent progenitor content.
The assay has numerous basic research and clinical
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the therapeutic potential of MSCs.
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